#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17738	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2437	890.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1832	1832	T	1137	T,G,C,A	1131,2,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17738	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2437	890.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1566	1566	C	1131	C,A,G	1128,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17738	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2437	890.5	0	HET	.	.	.	A69G	.	69	69	A	451	451	A	1121	A,G	871,249	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17738	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2437	890.5	0	HET	.	.	.	C262T,A,G	.	262	262	C	644	644	C	1041	C,T,A,G	797,241,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29732	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3976	931.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1878	1878	A	1213	A,T,G,C	1209,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29732	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3976	931.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2512	2512	C	1004	C,G,A	1002,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29732	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3976	931.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2586	2586	A	947	A,T	945,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29732	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3976	931.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3138	3138	C	1054	C,G	1053,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2880	folP	852	852	99.88	folP.l15.c4.ctg.1	1974	181.7	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1036	1038	AAA	296;297;295	A,C;A;A,G	295,1;297;294,1	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2880	folP	852	852	99.88	folP.l15.c4.ctg.1	1974	181.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1267	1269	AGC	273;274;275	A;G,T;C	273;273,1;275	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6818	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3894	218.5	1	SNP	p	S91F	0	.	.	271	273	TCC	822	824	TCC	246;243;243	T;C;C	246;243;243	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6818	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3894	218.5	1	SNP	p	D95N	0	.	.	283	285	GAC	834	836	GAC	246;245;248	G;A;C,A	246;245;247,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6818	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3894	218.5	1	SNP	p	D95G	0	.	.	283	285	GAC	834	836	GAC	246;245;248	G;A;C,A	246;245;247,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	2550	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1618	195.9	1	SNP	p	G45D	0	.	.	133	135	GGC	632	634	GGC	309;309;310	G,A;G,T;C	306,2;307,1;309	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1364	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1466	115.9	0	.	n	.	0	A197.	DEL	197	197	A	807	807	A	289	A	289	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6538	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3420	238.5	1	SNP	p	D86N	0	.	.	256	258	GAC	797	799	GAC	301;305;306	G;A;C	301;305;306	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6538	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3420	238.5	1	SNP	p	S87R	0	.	.	259	261	AGT	800	802	AGT	306;306;304	A,C;G,A;T	305,1;305,1;304	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6538	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3420	238.5	1	SNP	p	S87W	0	.	.	259	261	AGT	800	802	AGT	306;306;304	A,C;G,A;T	305,1;305,1;304	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6538	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3420	238.5	1	SNP	p	S87I	0	.	.	259	261	AGT	800	802	AGT	306;306;304	A,C;G,A;T	305,1;305,1;304	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6538	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3420	238.5	1	SNP	p	S88P	0	.	.	262	264	TCC	803	805	TCC	304;305;306	T;C;C,A	304;305;305,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5580	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3072	226.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1827	1829	GGC	293;294;295	G,C;G;C	292,1;294;295	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4704	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2875	204.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1483	1485	GCA	270;268;267	G;C;A	270;268;267	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4704	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2875	204.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1486	1488	ATC	268;269;268	A;T;C,A	268;269;267,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4704	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2875	204.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1498	1500	GTG	273;276;277	G;T,C;G,T	273;275,1;276,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4704	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2875	204.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1498	1500	GTG	273;276;277	G;T,C;G,T	273;275,1;276,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4704	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2875	204.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2002	2004	ACC	255;256;256	A,C;C;C	254,1;256;256	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4704	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2875	204.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2056	2058	GCG	240;238;237	G,T,C,A;C;G,T,C,A	237,1,1,1;238;234,1,1,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4704	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2875	204.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2056	2058	GCG	240;238;237	G,T,C,A;C;G,T,C,A	237,1,1,1;238;234,1,1,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4704	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2875	204.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2179	2181	GGC	260;260;261	G;G,T;C	260;259,1;261	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4704	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2875	204.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2188	2190	GGC	268;271;275	G,T;G,T,C;C,A	267,1;269,1,1;274,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4704	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2875	204.1	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2206	2208	CTG	295;291;289	C,A;T,G,C;G	294,1;287,2,2;289	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6574	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	3401	240.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1786	1788	CCG	253;255;252	C;C;G	253;255;252	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3406	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2171	195.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	708	708	C	273	C,T	272,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	308	porB1a	984	156	92.95	porB1a.l15.c17.ctg.2	156	47.3	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	22;23;26	T;T;A	22;23;26	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	308	porB1a	984	156	92.95	porB1a.l15.c17.ctg.2	156	47.3	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	59;59;59	C;A;T	59;59;59	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	308	porB1a	984	156	92.95	porB1a.l15.c17.ctg.2	156	47.3	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	59;59;59	A;G;T	59;59;59	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	308	porB1a	984	156	92.95	porB1a.l15.c17.ctg.2	156	47.3	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	59;59;59	T;A;C	59;59;59	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	308	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	182	57.7	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	73;69;69	A;C;G	73;69;69	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	308	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	182	57.7	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	21;18;17	C;A;A	21;18;17	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3354	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	2074	201.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	664	666	GAA	289;291;292	G,T,C;A;A	287,1,1;291;292	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3354	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	2074	201.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	952	954	GAT	277;276;274	G;A,C;T,C	277;275,1;272,2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3354	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	2074	201.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1075	1077	TCA	303;297;294	T,A;C;A	302,1;297;294	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3354	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	2074	201.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1204	1206	GTC	307;304;302	G;T;C,A	307;304;301,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3354	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	2074	201.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1534	1536	GCA	259;260;264	G,T;C,T;A,C	258,1;259,1;263,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3354	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	2074	201.7	1	SNP	p	G120K	1	.	.	358	360	AAG	910	912	AAG	269;269;267	A,C;A,C;G	267,2;267,2;267	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3354	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	2074	201.7	1	SNP	p	A121D	1	.	.	361	363	GAC	913	915	GAC	270;268;271	G;A;C	270;268;271	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3354	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	2074	201.7	1	SNP	p	D121N	0	.	.	361	363	GAC	913	915	GAC	270;268;271	G;A;C	270;268;271	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11324	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5286	267.0	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2185	2187	AAT	281;279;277	A;A;T	281;279;277	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1718	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1359	156.6	1	SNP	p	V57M	1	.	.	169	171	ATG	663	665	ATG	309;310;310	A;T;G	309;310;310	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
